Browsing Health Sciences by Subject "Parkinson se siekte"
Now showing items 1-10 of 12
-
Affinity of dihydropyrimidone analogues for adenosine A1 and A2A receptors
(2014)Parkinson’s disease (PD) is a neurodegenerative disorder that is characterised by a reduction of dopamine concentration in the striatum due to degeneration of dopaminergic neurons in the substantia nigra. Currently, first ... -
Aminopyrimidine derivatives as adenosine antagonists
(2013)Aims of this project - The aim of this study was to design and synthesise novel 2-aminopyrimidine derivatives as potential adenosine A1 and A2A receptor antagonists. Background and rationale - Parkinson’s disease is the ... -
Design and synthesis of dual acting carbamate inhibitors of acetylcholinesterase and monoamine oxidase
(North-West University (South Africa) , Potchefstroom Campus, 2017)Alzheimer’s disease (AD), the most common neurodegenerative disorder, affects about 10% of the population over the age of 65 years. The disease is typified by symptoms such as memory loss and impairment in abilities including ... -
Inhibition of monoamine oxidase by selected 8–[(phenylsulfanyl)methyl]caffeine derivatives
(North-West University, 2012)Purpose: Monoamine oxidase (MAO) consists of two isoforms, namely MAO-A and MAO-B. Both these isoforms are involved in the oxidation of dopamine. In Parkinson’s disease (PD) therapy, the inhibition of the oxidation of ... -
Monoamine oxidase inhibition by indanone and benzoquinone analogues
(North-West University (South Africa) , Potchefstroom Campus, 2015)Parkinson’s disease (PD) is a neurological disorder of which aging is the greatest risk factor. Over the next fifteen years, the number of persons affected by PD worldwide is expected to increase from 4.6 million to 9.3 ... -
The monoamine oxidase inhibition properties of caffeine analogues containing saturated C–8 substituents
(North-West University, 2010)Parkinson’s disease (PD) is a progressive neurodegenerative disorder, characterized pathologically by a marked loss of dopaminergic nigrostriatal neurons and clinically by disabling movement disorders. PD can be treated ... -
Monoamine oxidase inhibitory activities of heterocyclic chalcones
(2013)Parkinson’s disease is the second most common age-related neurodegenerative disease after Alzheimer’s disease. The characteristic pathological feature of Parkinson’s disease is the loss of neurons in the substantia nigra ... -
Novel sulfanyl– and sulfinylcaffeine analogues as inhibitors of monoamine oxidase
(North-West University, 2013)Parkinson’s disease (PD) is a neurodegenerative disorder, which is progressive in nature and usually associated with the elderly. It is the second most common age-related neurodegenerative disorder after Alzheimer’s disease ... -
Prescribing patterns of medicines used in Parkinson's and other related diseases in the private health care sector of South Africa
(North-West University, 2010)Parkinson's disease is the most recurrent movement disorder and has a radical effect on the lives of people. This chronic neurological disorder is accompanied by a significant social and financial burden with a negative ... -
Synthesis and biological evaluation of 6-substituted coumaranone derivatives and related compounds as monoamine oxidase inhibitors
(2014)Parkinson’s disease (PD) is an age related neurodegenerative disorder that presents with both motor and non-motor symptoms. The most common pathological characteristic of PD is the loss of the pigmented dopaminergic neurons ...
